Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough
A Phase 3 study is underway to evaluate the efficacy and safety of BLU-5937 in adults with refractory chronic cough.
Therapeutic Area
Therapeutic area intelligence for Chronic Cough with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.